Literature DB >> 14636825

Differing effects of two iron compounds on experimental arthritis, TNF-alpha levels and immune response in mice.

Marija Poljak-Blazi1, Boska Hrvacić, Zeljko Zupanović, Mirko Hadzija, Barbara Stanić, Denis Polancec.   

Abstract

The effects of ferric-sorbitol-citrate and ferric-citrate on the severity of experimental arthritis, TNF-alpha secretion and the immune status were examined in mice. Arthritis was induced by footpad injection of methylated BSA and intraperitoneal injection of Bordetella pertussis. Joint and footpad swelling were measured weekly by a caliper. TNF-alpha serum levels were measured by ELISA. The immune status was determined by the response of mouse lymphocytes to ConA in vitro and by the antigen-presenting cell assay. Experimental arthritis was aggravated by ferric-citrate, whereas ferric-sorbitol-citrate did not promote it. If applied to normal (non-arthritic) mice three times a week for 4 weeks, ferric-sorbitol-citrate stimulated isolated splenocytes to increase production of TNF-alpha, the function of antigen-presenting cells and lymphocyte proliferation in response to ConA in vitro. TNF-alpha production by cultured splenocytes was also stimulated. In mice with antigen-induced arthritis, iron compounds did not additionally stimulate TNF-alpha production. Thus, we have shown that ferric-sorbitol-citrate stimulated TNF-alpha production, antigen-presenting cell activity and cellular immune response. Development of antigen-induced arthritis and TNF-alpha production in arthritic mice were not stimulated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14636825     DOI: 10.1016/S1567-5769(03)00204-2

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  1 in total

1.  iTRAQ and PRM-Based Proteomic Analysis Provides New Insights into Mechanisms of Response to Triple Therapy in Patients with Rheumatoid Arthritis.

Authors:  Jian Chen; Shu Li; Yan Ge; Jin Kang; Jia-Fen Liao; Jin-Feng Du; Jing Tian; Xi Xie; Fen Li
Journal:  J Inflamm Res       Date:  2021-12-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.